Zhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%

MT Newswires Live

2025/01/02

Zhaoke Ophthalmology's (HKG:6622) phase 3 trial of its TAB014 treatment for wet (neovascular) age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.

The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.

Shares jumped 7% during Thursday's trading.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2500991078"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500991078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2500991078?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 13:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500991078","market":"nz","top_or_hot":-1,"title":"Zhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Zhaoke Ophthalmology's (HKG:6622) phase 3 trial of its TAB014 treatment for wet (neovascular) age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.</p><p>The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.</p><p>Shares jumped 7% during Thursday's trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-02 13:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zhaoke Ophthalmology's (HKG:6622) phase 3 trial of its TAB014 treatment for wet (neovascular) age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.</p><p>The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.</p><p>Shares jumped 7% during Thursday's trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500991078","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500991078","pubTimestamp":1735797220,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhaoke Ophthalmology's  phase 3 trial of its TAB014 treatment for wet  age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.Shares jumped 7% during Thursday's trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","06622":"兆科眼科-B","BK1191":"制药","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"兆科眼科黄斑变性药物3期试验达到终点；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":0.9},"content_text":"Zhaoke Ophthalmology's (HKG:6622) phase 3 trial of its TAB014 treatment for wet (neovascular) age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.Shares jumped 7% during Thursday's trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}